Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion Pharmaceuticals' AI-driven platform identified a drug candidate for solid tumors and lymphoma, gaining FDA approval for a phase 1/2 trial in under 18 months. The trial for REC-1245, targeting RBM39, will start in Q4 and aims to treat advanced HR-proficient cancers. Recursion plans to merge with Exscientia to leverage more data.
Recursion Pharmaceuticals' Groundbreaking Cancer Drug Enters Clinical Trials
Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account typically reactivates within 24 hours; contact support if still disabled.
Recursion Announces FDA Clearance of Investigational New
Recursion's AI-enabled platform led to the FDA clearance of REC-1245, a Phase 1/2 clinical trial drug for biomarker-enriched solid tumors and lymphoma, identified and optimized in under 18 months.
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245
Recursion (NASDAQ: RXRX) received FDA clearance for REC-1245, a potential first-in-class RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma, developed in under 18 months. A Phase 1/2 trial is planned for Q4 2024, with an estimated addressable population of over 100,000 in the US and EU5.
Recursion gains FDA clearance for Phase 1/2 cancer drug trial
Recursion received FDA clearance for a Phase 1/2 trial of REC-1245, targeting solid tumors and lymphoma, set to start in Q4 2024. The drug, developed using AI, targets RBM39, potentially addressing a significant unmet need. Recursion's platform combines experimental and computational approaches for drug discovery. The company, listed on NASDAQ: RXRX, is based in Salt Lake City and part of the Utah life sciences collective, BioHive.
Recursion Announces FDA Clearance of Investigational New Drug for Phase 1/2 Trial Targeting Solid Tumors and Lymphoma
Recursion announced FDA clearance for a Phase 1/2 trial of REC-1245, targeting solid tumors and lymphoma, leveraging AI for rapid drug discovery. The trial, set for Q4 2024, aims to evaluate REC-1245's safety and efficacy, highlighting Recursion's innovative approach to industrializing drug discovery with its AI-enabled platform.
Artificial Intelligence (AI) in Life Sciences Research
The AI in Life Sciences Market was $8B in 2023, expected to reach $33.5B by 2029, growing at a CAGR of 27.9%. Software led with 65.6% share in 2023, clinical and molecular diagnostics with 28.9%, and contract research organizations with 64.5%. North America dominated with a projected CAGR of 28.1%. Key companies profiled include AiCure, Apixio, Atomwise, BenevolentAI, and NuMedii.
© Copyright 2025. All Rights Reserved by MedPath